drugset / Trial / NCT01584544

Safety Study of Capecitabine With Radiation in Elderly Rectal Cancer

NCT01584544 ↗

Phase 1 Completed 24 enrolled Chinese Academy of Medical Sciences
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This phase I study is designed to determine the maximum tolerant dose of capecitabine when used in preoperative concurrent chemo-radiation for locally advanced rectal patients over 75 years old.

Timeline

Start
2011-01
Primary completion
2014-05
Completion
2014-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1000 mg/m2 Oral
Subject Capecitabine Small molecule 1200 mg/m2 Oral
Subject Capecitabine Small molecule 1350 mg/m2 Oral
Subject Capecitabine Small molecule 1500 mg/m2 Oral
Subject Capecitabine Small molecule 1650 mg/m2 Oral

Indications